A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation

Blood

Volumn 113, Issue 21, 2009, Pages 5206-5216

  Gupta, Mamta ^a   Dillon, Stacey R ^b   Ziesmer, Steven C ^a   Feldman, Andrew L ^a   Witzig, Thomas E ^a   Ansell, Stephen M ^a   Cerhan, James R ^a   Novak, Anne J ^a  

^a MAYO CLINIC   (United States)

^b ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CYCLIN D1; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN; S6 KINASE; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; PROTEIN KINASE; TNFRSF13B PROTEIN, HUMAN; TNFSF13 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; B-LYMPHOCYTES; CELL PROLIFERATION; CYCLIN D1; HUMANS; LYMPHOMA, FOLLICULAR; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; UP-REGULATION;

EID: 67149099805     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-179762     Document Type: Article

References (67)

1. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747-1756. (Pubitemid 29272691)
2. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260-263. (Pubitemid 29330000)
3. Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188:1185-1190. (Pubitemid 28443341)
4. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18:263-275. (Pubitemid 44287558)
5. Yu G, Boone T, Delaney J, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000;1:252-256.
6. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cells. 2004;6:399-408. (Pubitemid 39361440)
7. He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004;172:3268-3279. (Pubitemid 38263719)
8. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia Bcell survival through activation of the canonical NF-κB pathway. Blood. 2007;109:703-710. (Pubitemid 46105972)
9. Madry C, Laabi Y, Callebaut I, et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol. 1998;10:1693-1702. (Pubitemid 28502383)
10. von Bulow GU, Russell H, Copeland NG, et al. Molecular cloning and functional characterization of murine transmembrane activator and CAML interactor (TACI) with chromosomal localization in human and mouse. Mamm Genome. 2000;11:628-632. (Pubitemid 30622251)
11. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-2111. (Pubitemid 32848062)
12. Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11:1547-1552. (Pubitemid 32931019)
13. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173:807-817. (Pubitemid 38924255)
14. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity. 2001;14:573-582.
15. Seshasayee D, Valdez P, Yan M, et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003;18:279-288. (Pubitemid 36263002)
16. Yan M, Wang H, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001;2:638-643. (Pubitemid 32677632)
17. Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37:829-834. (Pubitemid 41077108)
18. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37:820-828. (Pubitemid 41077107)
19. Sakurai D, Kanno Y, Hase H, et al. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol. 2007;37:110-118. (Pubitemid 46128791)
20. Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med. 2005;201:1375-1383. (Pubitemid 40664082)
21. Hendriks J, Planelles L, de Jong-Odding J, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 2005;12:637-648. (Pubitemid 40767166)
22. Sakurai D, Hase H, Kanno Y, et al. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood. 2007;109:2961-2967. (Pubitemid 46482094)
23. Bischof D, Elsawa SF, Mantchev G, et al. Selective activation of TACI by syndecan-2. Blood. 2006;107:3235-3242.
24. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004;104:2247-2253. (Pubitemid 39331819)
25. Xia XZ, Treanor J, Senaldi G, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med. 2000;192:137-143. (Pubitemid 30470815)
26. Fox BA, Moore MD. Trimerizing polypeptides. WO 2007/030803 A2. US Priority Date, September 9, 2005.
27. Novak AJ, Bram RJ, Kay NE, et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 2002;100:2973-2979.
28. Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995;85:997-1005.
29. Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689-694.
30. Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007;109:729-739. (Pubitemid 46105975)
31. Huard B, Arlettaz L, Ambrose C, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol. 2004;16:467-475. (Pubitemid 38313155)
32. Schwaller J, Schneider P, Mhawech-Fauceglia P, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B cell lymphoma aggressiveness. Blood. 2006;109:331-338. (Pubitemid 46053074)
33. Dillon SR, Gross JA, Ansell SM, et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006;5:235-246.
34. Woodland RT, Fox CJ, Schmidt MR, et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood. 2008;111:750-760.
35. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-262.
36. Jelinek DF, Darce JR. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun. 2005;8:266-288.
37. Rennert P, Schneider P, Cachero TG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000;192:1677-1684.
38. Salzer U, Jennings S, Grimbacher B. To switch or not to switch-the opposing roles of TACI in terminal B cell differentiation. Eur J Immunol. 2007;37:17-20. (Pubitemid 46128781)
39. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science. 1997;278:138-141.
40. Benson RJ, Hostager BS, Bishop GA. Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K. Eur J Immunol. 2006;36:2535-2543.
41. Deregibus MC, Buttiglieri S, Russo S, et al. CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. J Biol Chem. 2003;278:18008-18014. (Pubitemid 36799410)
42. Burow ME, Weldon CB, Melnik LI, et al. PI3-K/AKT regulation of NF-κB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun. 2000;271:342-345.
43. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-999. (Pubitemid 30243593)
44. Hatzoglou A, Roussel J, Bourgeade MF, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-κB, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 2000;165:1322-1330.
45. Franke TF, Kaplan DR, Cantley LC, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997;275:665-668.
46. Klippel A, Kavanaugh WM, Pot D, et al. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol. 1997;17:338-344. (Pubitemid 26425623)
47. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606-619. (Pubitemid 44100518)
48. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-657. (Pubitemid 34993700)
49. Manning BD, Tee AR, Logsdon MN, et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10:151-162. (Pubitemid 34876569)
50. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4:658-665. (Pubitemid 34993701)
51. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101.
52. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell. 2007;12:487-502.
53. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122-1128. (Pubitemid 39468014)
54. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296-1302.
55. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem. 2003;278:15461-15464. (Pubitemid 36799651)
56. Schalm SS, Fingar DC, Sabatini DM, et al. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol. 2003;13:797-806.
57. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729-734.
58. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997;410:78-82.
59. Lin TA, Kong X, Haystead TA, et al. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science. 1994;266:653-656. (Pubitemid 24363524)
60. Pause A, Belsham GJ, Gingras AC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5-cap function. Nature. 1994;371:762-767. (Pubitemid 124000078)
61. Peterson RT, Schreiber SL. Translation control: connecting mitogens and the ribosome. Curr Biol. 1998;8:R248-R250.
62. Ewen ME, Sluss HK, Sherr CJ, et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993;73:487-497. (Pubitemid 23143348)
63. Hunter T, Pines J. Cyclins and cancer, II: cyclin D and CDK inhibitors come of age. Cell. 1994;79:573-582.
64. Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106:1021-1030. (Pubitemid 41076449)
65. Moreaux J, Hose D, Jourdan M, et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica. 2007;92:803-811. (Pubitemid 350155306)
66. Cantley LC. The role of phosphoinositide 3-kinase in human disease. Harvey Lect. 2004;100:103-122.
67. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356. (Pubitemid 46206988)